Physician profile
Richard A Mann
NPI 1598785883
$472.24
in general payments reported to CMS, 2019-2025
9 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $37.32 · 2023: $119 · 2024: $83.81 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $323.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $120.42 | 2025 | Tarpeyo |
| Ethicon US, LLC | $111.48 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.82 | 2023-2024 | Livtencity |
| Merck Sharp & Dohme LLC | $38.79 | 2024 | Prevymis, Dificid |
| Baxter Healthcare | $37.32 | 2020 | |
| Alexion Pharmaceuticals, INC. | $36.91 | 2023 | Ultomiris |
| Daiichi Sankyo INC. | $32.09 | 2023 | Injectafer |
| Irhythm Technologies, INC. | $28.61 | 2024 | Zio Xt Patch, Zio Monitor |
| Glaxosmithkline, LLC. | $16.80 | 2023 | Benlysta, Jesduvroq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.